The purpose of this study is to investigate the effects of experimental medication BMS-986278 given with the antibiotic Rifampin in healthy participants.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
39
Oral administration 30 mg
Oral administration 600 mg
PRA Health Science KK
Lenexa, Kansas, United States
Maximum observed plasma concentration (Cmax) for BMS-986278
Time frame: Day 1 and 8
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] for BMS-986278
Time frame: Up to 24 days
Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] for BMS-986278
Time frame: Day 1 and 8
Terminal phase half-life (T-HALF) for BMS-986278
Time frame: Day 1 and 8
Incidence of non-serious adverse events (AE)
Time frame: Up to 24 days
Incidence of serious adverse events (SAE)
Time frame: Up to 24 days
Incidence of AE leading to discontinuation
Time frame: Up to 24 days
Incidence of clinically significant changes in vital signs, electrocardiograms (ECGs), physical examinations, and clinical laboratory tests
Time frame: Up to 24 days
Maximum observed plasma concentration (Cmax) for Rifampin
Time frame: Day 8
Time of maximum observed plasma concentration (Tmax) for Rifampin
Time frame: Day 8
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] for Rifampin
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Day 8-9
Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] for Rifampin
Time frame: Day 8-9